Molecular Foundations: MDMA and Psilocybin
250 CAD + tax

Format: Asynchronous, online
Instructors: Content was written in consultation with Dr. Devon Christie, MD, CCFP, IFMCP, RTC and Cody Callon, MSW
Duration: 8 hours

This course will bring you on a journey through the effects elicited by MDMA and psilocybin on the body and mind as it relates to psychedelic-assisted therapy. The content developed for this course is based on current literature and research and analyzed through the lens of trauma and violence-informed care and through commitments to social justice, equity, dignity, inclusion, cultural safety, and humility.

In the course, you will learn about the dose ranges, indications, contraindications, and concomitant medications of MDMA and psilocybin. You will also learn about some fundamental pharmacology and neurobiology as it relates to the administration of MDMA and psilocybin in psychedelic-assisted therapy.

Continuing Education (CE) accreditation will be available upon completion. This course can be completed at your own pace whenever it is most convenient for you, however the course must be completed within 1 year of your registration date. If the course is not completed after 1 year, you will not be eligible for a refund, and you will need to re-register.
PHRI

Explore the molecular foundations of MDMA and psilocybin

This set of two courses is geared towards mental health professional and therapists who want to learn more about the molecular structure of MDMA and psilocybin. In each course, you will learn about the dose ranges, indications, contraindications, and concomitant medications of each psychedelic medicine. You will also learn about some fundamental pharmacology and neurobiology as it relates to the administration of psychedelic medicines in psychedelic-assisted therapy.

Consider also registering for the Molecular Foundations of ketamine courses.

Learning Objectives

By the end of this workshop, participants will know more about how to:

  • Apply pharmacological knowledge of MDMA and psilocybin to the facilitation or development of a psychedelic-assisted therapy protocol in a clinical setting.
  • Compare the wide range of effects, side effects, effects of long-term use, and abuse potential of MDMA and psilocybin.
  • Apply cultural safety and humility to the administration of MDMA and psilocybin as part of psychedelic-assisted therapy in order to avoid cultural appropriation and cultural harm.
  • Screen clients and determine if MDMA and psilocybin would be best suited for a given client or clinical presentation.
PHRI

About Cody Callon, MSW

Cody has over 15 years experience as a social worker and researcher in the field of addictions and mental health. He addresses issues such as addiction, trauma, depression, anxiety, relationships, grief and loss, and personal growth. Cody has a Bachelor of Arts degree in Psychology and a Master of Social Work degree from University of British Columbia. Cody is also a graduate of the California Institute of Integral Studies Psychedelic-assisted Psychotherapy and Research certificate program and has additional training in mdma- and ketamine-assisted therapy.

Cody is the Lead of Psychedelic Programs and Numinus where he provides ketamine-assisted therapy and is contributing to the development of a variety of clinical and research programs. He has also served as a therapist on a study using MDMA-assisted psychotherapy to treat post-traumatic stress disorder.

Cody's therapeutic orientations include relational somatic therapy, compassionate inquiry, mindfulness based counseling, and motivational interviewing. Cody is passionate about providing preparation and integration support for people working with plant medicines and psychedelics. Cody draws from his academic training, professional experiences, psychedelic research, and his own medicine work and contemplation practices to inform his work.





Deanna Rogers

About Dr. Devon Christie MD, CCFP, IFMCP, RTC

Dr. Devon Christie MD is a clinical instructor with the UBC Department of Medicine and has a focused practice in chronic pain management. She is also a Registered Counsellor emphasizing Relational Somatic Therapy for trauma resolution, and a certified Mindfulness Based Stress Reduction teacher (UCSD). She is trained to deliver both MDMA-assisted psychotherapy for PTSD (MAPS USA) and ketamine-assisted psychotherapy. She teaches for the California Institute of Integral Studies Certificate Program in Psychedelic Therapy and Research, the Integrative Psychiatry Institute Certificate Program in Psychedelic Assisted Therapy, and the ONCA Foundation Psychedelic Therapy program. She is a Principal Investigator and study therapist for a current Canadian MAPS PBC-sponsored 20-participant open-label clinical trial investigating MDMA-assisted psychotherapy for PTSD. Devon is the Medical and Therapeutic Services Director with Numinus Wellness Inc., and is a recognized speaker and expert on the potential for incorporating psychedelic assisted therapies in an improved health care model for the future.





Dr. Devon Christie

FAQs

  • Will a certificate of completion be offered to participants?
    • Yes - for 4 hours per course (ketamine, MDMA, psilocybin)
  • Are there any live sessions in these courses?
    • No - the Molecular Foundations courses are entirely asynchronous and can be completed to your own schedule.
  • Can I register even if I live outside of Canada
    • Yes - absolutely


    Refund Policy

    If you are unable to attend the course, please send an e-mail confirming your cancellation to training@numinus.com. A 10% administration fee will be charged for any cancellations, based on the total cost of the course, plus tax. If you have any questions, please reach out to our team and we would be happy to support you.



    Disclaimer

    The continuing professional development program in no way promotes, condones, or facilitates illegal activity, and is strictly for educational and harm reduction purposes only. Please be aware that certain psychedelic substances still remain illegal in many jurisdictions, including Canada. This program and the contents of this website do not constitute medical advice, and are not a substitute for professional medical advice and treatment.